vitamin K, and why breast milk contains very little. Even before reading Professor Golding's studiesl 2 and the attendant press publicity, most had reviewed their vitamin K policy at intervals in order to try to spare newborn babies intramuscular injections. Some were already using oral vitamin K despite the lack of a suitable licensed preparation.3 A single oral dose regimen is now known not to be fully protective against late haemorrhagic disease of the newborn (HDN). 4 5 The high profile which the debate then enjoyed, and the recommendations of the British Paediatric Association (BPA) published in November 1992, caused many more units to change their policy and to reduce the prescribed dose both of oral and intramuscular vitamin K. Review of 50 protocols received in response to a request for information in the BPA newsletter of spring 1993 reveals that current UK practice is now more varied than during the last survey.6 Parental consent is much more widely sought, although not all practitioners are willing to take responsibility for oral administration of vitamin K so that some infants are discharged unprotected if parents refuse the parenteral route. Doses prescribed include 500, 250, 200, and 100 pug intramuscularly with or without subsequent oral doses, and some use 1 mg or 500 pug of vitamin K as a single oral dose. Many have adopted the regimen of 500 ,ug divided into two doses on the first day of life with two subsequent doses of 250 ,ug at intervals in breast fed babies. Some are giving as many as five repeat oral doses and most specify that intramuscular doses should continue to be given to 'high risk' babies, although the definition of this group is not uniform. In particular not all include maternal anticonvulsant treatment, none mention maternal antituberculous treatment, and some add a family history of bleeding disorder or bruising in the baby. Vitamin K prophylaxis is clearly essential, and it is now obvious that repeated oral dosing will be required in breast fed infants. The best oral regimen required to prevent late HDN has yet to be defined. Multiple oral dosing will always be less reliable than the intramuscular route due to non-compliance and malabsorption. However, it has philosophical advantages and will prove more acceptable to parents. A unified approach is required in the UK as any individual cannot hope to establish the risks of the preferred regimen in his or her own practising lifetime. Using the information from the last British Paediatric Surveillance Unit (BPSU) survey, if all 'normal risk' UK infants were given one dose of oral vitamin K there would be about 20 cases of late HDN per annum in the whole country. The best way of reducing this to zero and reliably confirming the reduction needs to be carefully thought through; the logistics of a trial involving half a million deliveries would make such a study virtually impossible and a common protocol adhered to for several years is the only practical approach. When Konakion MM becomes available a four dose oral regimen should be universally adopted and monitored by the BPSU. Until his time the only certain and licensed regimen remains 1 mg intramuscular vitamin K. The infrastructure exists for routine administration at birth and the system has worked well for many years. Routine intramuscular administration has the benefit of simplicity, and avoids the necessity of identifying Rennie, Kelsall breast feeding mothers and those on anticonvulsant therapy and the uncertainty of predicting liver disease. For those who are not prepared to return to the intramuscular route while awaiting Konakion MM an initial oral dose of 500 ,ug in two divided doses giving the existing form should be prescribed. At least two further doses must be arranged for breast fed babies and will also be required if the intramuscular dose used for those considered to be at high risk is 100 pug. Death from late HDN after a single intramuscular dose of this size has already been reported from Australia.27 A bitter lesson has again been learned from the release of important new research results to the national press before most of the profession have been able to read the original paper and before a response from a suitably qualified expert group has been drafted and discussed. As a consequence of this latest scare, some babies have been put at increased risk of developing HDN by being denied prophylaxis by their parents or doctors, and mothers may be less likely to breast feed as they perceive that bottle feeding provides adequate sources of vitamin K. Paediatricians should do all they can to redress the balance in this debate by presenting a balanced view.
